Aims Ingestion of grapefruit juice (GFJ) alters the pharmacokinetics of various orally administered drugs. Quantitative evaluation of this GFJ-drug interaction is required for the proper clinical management of patients. Methods Using felodipine as a model drug, we constructed a pharmacokinetic model based on irreversible inhibition of intestinal cytochrome P450 3A4 (CYP3A4) by GFJ. We fitted previously publised data [5, 6] for felodipine ER (extended release formulation) to the ratio of CL GI,int before and after grapefruit juice ingestion by nonlinear least-squares regression analysis to estimate the reaction rate constant between GFJ and CYP3A4 (K) and the elimination rate constant of CYP3A4 (k). Results The model gave a turnover rate of CYP3A4 of 0.0849 h −1 , corresponding to a half-life of 8.16 h, in agreement with reported values. The AUC-time profiles of felodipine ER in the case of different amounts and schedules of GFJ ingestion were simulated using the parameter values estimated from the model. Conclusions The modelling leads to the important conclusion that GFJ-felodipine interaction increases with increasing frequency and amount of GFJ ingestion, and that an interval of 2-3 days between GFJ intake and felodipine administration is necessary if GFJ-felodipine interaction is to be avoided.
Introduction and either substrates or inhibitors of P-glycoprotein (P-gp) [24] . Therefore, the mechanism of the GFJ-drug There have been a number of reports showing that the oral intake of grapefruit juice (GFJ) results in increased interaction is thought to involve inhibition of drug metabolism by CYP3A and and/or inhibition of drug plasma concentrations of several clinically used drugs administered orally, including dihydropyridine-type calefflux by P-gp [2, 25, 26] in the intestine. The relative contributions of these mechanisms to the increase in the cium antagonists such as felodipine [1] [2] [3] [4] [5] [6] [7] [8] [9] , nifedipine [3, 10], nisoldipine [11] , nitrendipine [12] , and verapamil plasma concentration of drugs in the presence of GFJ seem to be determined by the differences in the affinities of [13] , terfenadine [14] , cyclosporin A [15, 16] , diazepam [17] , midazolam [18] , triazolam [19] , saquinavir [20] , the drugs for the two proteins. Since CYP3A4 is a major drug-metabolizing enzyme in human intestine, it appears ethinylestradiol [21] , caffeine [22] and tacrolimus [23] . In contrast, the ingestion of GFJ does not alter the plasma that some components of GFJ inhibit drug metabolism by intestinal CYP3A4 [2, 27] , and dihydroxybergamottin concentrations of felodipine [7] , nifedipine [10] , midazolam [18] and cyclosporin A [15] after intravenous drug [27] , bergamottin [28] and GF-I-1 [29] have been identified as candidate inhibitors. We found that these administration. This finding suggested that GFJ influences drug absorption in the intestine. The above drugs are furanocoumarin derivatives also inhibit P-gp function in Caco-2 cells [30] . However, calcium antagonists of the Quantitative prediction of the GFJ-drug interaction is where Q H and CL iv are the hepatic blood flow and the total body clearance (CL iv ) after intravenous adminisimportant in order to protect patients from possible adverse effects. In this study, we developed a pharmacotration, respectively. CL iv is 844.2 ml min −1 (obtained from Lundahl's report [7] ). We assumed that the CL GI,int kinetic model based on the irreversible inhibition of intestinal CYP3A4 by GFJ components, using felodipine does not contribute to the CL iv after intravenous administration of the drug. Since there is no positive as a model drug. The parameter values estimated from the model were used to predict the effect of amount and report that felodipine is secreted to the digestive tract and then metabolized after intravenous administration, it is frequency of GFJ ingestion on the drug clearance.
assumed that the CL GI,int does not contribute to the CL iv after intravenous administration of the drug.
Methods
The total clearance (CL oral ) after oral administration is Collection of data calculated as follows, For development of the pharmacokinetic model of CL oral =Dose/AUC (b) felodipine-GFJ interaction in this study, we utilized
The bioavailability in the liver ( F liver ) and the absolute pharmacokinetic data obtained from two clinical trials by bioavailability ( F) of the drug following oral intake are Lundahl et al. [5, 6] . In the first, nine healthy male given as follows, volunteers were given 10 mg felodipine ER orally F liver =Q H /(Q H +CL H,int ) (c) together with either 200 ml tap water or GFJ at 0, 1, 4, 10 or 24 h before administration of felodipine [5] . In the F=CL iv /CL oral =F abs ΩF GI ΩF liver (d) second, 12 healthy male volunteers received 10 mg If we assume F abs =1, the bioavailability in the intestine felodipine ER after daily intake of either 200 ml of tap ( F GI ) can be determined by using F and F liver =0.339 water or GFJ for 1 day or 14 days [6] .
[7]. This is based on the report that felodipine is almost completely absorbed [2] . F GI =F/F liver . Development of the model [31] [32] [33] [34] On the other hand, F GI can be expressed as follows, The developed model, based on irreversible inhibition of F GI =Q GI /(Q GI +CL GI,int ) (e) the drug-metabolizing enzyme CYP3A4 by components where Q GI is 898.3 ml min −1 , as calculated from of GFJ, is shown in Figure 1 . Q H 5Q GI =150.7034 and Q H (1277.2 ml min −1 ) First, the intestinal intrinsic clearance (CL GI,int ) and [35] [36] [37] [38] . hepatic intrinsic clearance (CL H,int ) are calculated in the Thus, CL GI,int can be determined by using equations absence of GFJ. It is assumed that felodipine is eliminated (a) (d) and (e). We can also determine the intestinal in the liver, not in the kidneys.
intrinsic clearance (CL∞ GI,int ) in the presence of GFJ by The CL H,int is determined based on the following the same procedure. equations,
The intestinal intrinsic clearance of felodipine CL iv =Q H ΩCL H,int /(Q H +CL H,int ) (CL∞ GI,int ) in the presence of GFJ and that in the absence of GFJ (CL GI,int ) can be determined as follows. 
k∞=0.0869±0.00112, AIC=−23.85 (for analysis II) where k a (h −1 ) and k e (h −1 ) are the inflow rate constant of GFJ from stomach to small intestine and the outflow where AIC is an information criterion. Analysis I shows a better agreement between prediction and observation rate constant of GFJ from small intestine to colon, respectively, and t (h) is the time since GFJ ingestion.
than analysis II, and this allowed us to decrease the number of parameters by using a single elimination C GFJ is an arbitrary value.
After oral administration of felodipine, GFJ induces a constant, k. significant increase of AUC compared with the control. The effect of GFJ on the metabolism of felodipine is Data analysis mediated mainly through selective downregulation of CYP3A4 in the small intestine, and the intestinal The pharmacokinetic parameters for gastrointestinal transit of GFJ, such as k a and k e , were estimated by using CYP2D6 and CYP1A1 protein content are not affected [2] . We have developed this mathematical model for the reported data on the behaviour of orally administered GFJ in stomach and intestine [39] . The k a value was purpose of explaining the GFJ-felodipine interaction based on these biochemical findings, and GFJ components determined as the reciprocal of gastric emptying time (0.30 h), i.e. 3.33 (h −1 ). The intestinal transit time are presumed to react specifically with CYP3A4 in intestinal cells, converting active CYP3A4 to inactive (4.10 h) was calculated from the difference between the gastric emptying time (0.30 h) and arrival time at CYP3A4 with a rate constant of
Furthermore, it is assumed that CYP3A4 is synthesized the colon (4.40 h). The k e value was determined as the reciprocal of the intestinal transit time, 0.244 (h −1 ). By at a constant rate, K s (mol h −1 ), and is eliminated with the first-order rate constant, k (h −1 ). Thus, the total using these parameters, the change of C GFJ was simulated according to equation (k). CL GI,int , CL∞ GI,int and e were CYP3A4 content, E t (mol) should be given by K s /k at calculated according to equations (a)-(e) by using data
Intestinal transition of GFJ obtained after the single oral administration of 10 mg felodipine ER with GFJ or water [4] and data obtained To simulate the intestinal GFJ concentration profile (C GFJ ), the inflow rate constant of GFJ from stomach to after the single oral administration of 10 mg felodipine ER following daily intake of GFJ or water for 14 days.
small intestine, k a (h −1 ), and the outflow rate constant of GFJ from small intestine to colon, k e (h −1 ) were used By using simulated C GFJ time profiles (equation k), etime profiles (7 points) were fitted to equations (n) and (see equation k). The C GFJ -time curves after single ingestion of GFJ or daily intake of GFJ for 14 days are (o) with the nonlinear least-squares regression analysis program MULTI (RUNGE) [40] and both K and k were shown in Figure 2a -I and Figure 2a -II, respectively. estimated. In this analysis, we wished to estimate the time-dependent change of felodipine AUC in the Estimation of the reaction rate constant (K) between GFJ and presence of grapefruit juice. But, AUC is the sum of the CYP3A4 and the elimination rate constant (k) of CYP3A4 area under the plasma concentration curve from administration time to infinity. Therefore, we used t max at the Based on the irreversible enzyme inhibition model (Figure 1 ), pharmacokinetic data (e-values-time profiles) time of C max as a measure of the interaction effectiveness with grapefruit juice. For convenience, we took t as of felodipine (Tables 1 and 2 ) after single or repeated ingestion of GFJ were fitted to equations (n) and (o) with t max +real time, since if t is simply taken as real time, the effect has a large value immediately after grapefruit the nonlinear least-squares regression analysis program in order to estimate K and k. The estimated values of K and ingestion, which seems unnatural and difficult to analyse.
By using the parameter values thus obtained and k were 0.922±0.0688 (AU −1 h −1 ) and 0.0849±0.00913
(h −1 ), respectively. The simulation curves and the equations (k), (n), (o), we simulated the time-dependent changes of the active CYP3A4 content ratio (e) and the observed values of active CYP3A4 ratio (e) and change of felodipine AUC after single or repeated ingestion of increase of felodipine AUC was calculated by use of the following equation in the case of various amounts (1, 2, GFJ are shown in Figure 2c -I, II and Figure 2d -I, II. Good agreement was found between the observed and 3, 4, 5 and 6 times the regular intake) and frequencies (1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 times per day) of predicted values. GFJ ingestion. Simulations were also conducted for drug administration after GFJ ingestion daily for 7 days and Simulation of the metabolic inhibition of CYP3A4 by GFJ three times per day for 7 days.
The inhibition-time profiles of felodipine metabolism AUC∞/AUC=DoseΩF∞/CL iv )/(DoseΩF/CL iv ) after ingestion of GFJ in various amounts and at various frequencies were simulated by using the estimated =F∞ GI /F GI parameters. We also simulated the profiles of the decline and recovery of e after three ingestions of GFJ in one =(Q GI /(Q GI +CL∞ GI,int ))/(Q GI /(Q GI +CL GI,int )) day, after one ingestion per day for 7 days, and after three ingestions per day for 7 days. =(R+1)/(R+e) (a) Effect of amount of GFJ ingested (1, 2, 3, 4, 5 and 6 where R is Q GI /CL GI,int .
times the regular amount) on time profile of e and AUC of felodipine As shown in Figure 4 , the e-value was immediately Results reduced to 0.2 by a single dose of GFJ, and to 0.1 by double that dose. When the amount of GFJ was increased Effects of drug administration time after ingestion of GFJ and 14 day ingestion of GFJ on metabolic clearance of felodipine to 3, 4, 5, 6 times the regular dose, there was little further change of the e-value. In each case, the e-value Table 1 and Table 2 show the pharmacokinetic data recovered to the control level (1.0) within 2 days (AUC, increase ratio of AUC, oral clearance (CL oral = (Figure 3a) . In a mirror image of the e-values, the AUC dose/AUC), t max (h), t (h), CL iv , F, F iv , F GI , Q H , Q GI , of felodipine increased immediately after GFJ ingestion. intestinal intrinsic clearance (CL GI,int ) and active enzyme
The maximum increase of AUC was about 1.7-fold. The ratio (e)) that were utilized for analysis in this study.
AUC values also recovered to the control level within Table 1 shows the pharmacokinetic data of felodipine 2 days (Figure 3b ). ER administered at 0, 1, 4, 10, or 24 h after intake of GFJ, while Table 2 shows the effect of ingestion of (b) Effect of frequency of GFJ ingestion (1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 times per day) on e and on the AUC of GFJ for 1 day or 14 days on the pharmacokinetic data of felodipine.
felodipine Table 1 Experimental data for interaction between single ingestion of GFJ and felodipine. The AUC and increase of AUC values are taken from Lundahl's data [3] . The experiments were always performed by starting in the morning after an overnight fast. On the study days the subjects were given 10 mg felodipine ER orally and either 200 ml tap water (control), or GFJ before the tablet. The juice was always prepared immediately before intake by diluting 50 ml of frozen concentrate with 150 ml tap water. CL∞, F∞ are clearance and availability after intake of grapefruit juice. e is the ratio of active CYP3A4 to total CYP3A4. AUC, increase (fold) of AUC and CL oral (oral clearance) were calculated with equation
Time from ingestion of GFJ to administration of felodipine (h)

(b) in Materials and Methods. t max (h) is the time of maximum plasma concentration, and t(h) is t max +(time after GFJ ingestion). Bioavailability ( F) and intestinal bioavailability ( F GI ) were calculated with equation (d), intestinal intrinsic clearance (CL GI,int ) was calcualted with equations (a), (d), (e), and metabolic activity for felodipine (e) was calcualted with equation ( j).
As shown in Figure 6 , the e-value immediately fell to 0.2 1 day was carried out. The e-value immediately fell to 0.2 after GFJ ingestion at 07.00 h, and to 0.1 after after one dose of GFJ, and to 0.05 after ingestion of GFJ 10 times in a day (Figure 4a) . Correspondingly, the GFJ ingestion at 12.00 h, and remained at 0.1 after the third GFJ ingestion at 18.00 h. Thereafter, it took 2.5 days AUC of felodipine was immediately increased 1.5-fold by GFJ ingestion. The maximum increase of the AUC for e to recover to the control level (Figure 5a) . Furthermore, the AUC of felodipine increased 1.5-fold was 1.65-fold after ingestion of GFJ 10 times in a day (Figure 4b) .
after the first dose of GFJ and further increased to about 1.6 times the control after the second and third doses. (c) Simulation of the time profiles of e and AUC of The AUC took 2.5 days to revert to the control level felodipine after three ingestions of GFJ in a day (Figure 5b) . A simulation study of e and AUC of felodipine after three ingestions of GFJ (at 07.00 h, 12.00 h, 18.00 h) in (d) Simulation of the time profiles of e and AUC of The AUC and increase of AUC values are taken from Lundahl's data [4] . In all experiments the subjects were given 10 mg felodipine ER daily for 14 days with either 200 ml grapefruit juice or 200 ml water (control). The juice was always prepared immediately before intake by diluting 50 ml frozen concentrate (Miracle Mart, Canada) with 150 ml tap water. The parameters are the same as those of Table 1. AUC ratio varied between 1.1 and 1.5, and also took 3 days to recover after the last GFJ ingestion (Figure 6b ). In the case of three GFJ ingestions per day for 7 days, the e-value varied between 0.1 and 0.4 and took 3 days to recover (Figure 6c ), while the AUC ratio varied between 1.3 and 1.6, again taking almost 3 days to recover to the control value after the last GFJ ingestion (Figure 6d ).
Discussion
Quantitative evaluation of this GFJ-drug interaction is required for the proper clinical management of patients. Therefore, we have constructed a pharmacokinetic model, using felodipine as a model drug. This model (Figure 1 ) was constructed on the assumption that CYP3A4 is down-regulated irreversibly by components of GFJ. the plain tablet. In this study, we did not take into consideration the variability of the interaction among subjects. However, it is considered that the variability of felodipine after once-daily or three-times-daily ingestions of GFJ for 7 days. The time profiles of e and AUC of the interaction among subjects is one of the important factor as well as the drug formulation on the prediction felodipine during once daily or three times daily (at 07.00 h, 12.00 h, 18.00 h) ingestions of GFJ for 7 days of the extent of the interaction. More detailed studies considering this important factor will be required to were simulated using the developed model. The e-value varied between 0.2 and 0.7 during a single GFJ ingestion predict the extent of the interaction between felodipine and GFJ. Moreover, the increase in AUC after grapefruit per day for 7 days, and took 3 days to recover to the control value after the last ingestion (Figure 6a ). The juice was significantly less for an ER formulation than for plain tablets [42] . This may be because of a progressive in the case of changing the ingested amount of GFJ (2, 3, 4, 5, 6 times the regular amount) increased by a decline in microsomal CYP3A content from duodenum to jejunum to ileum [43] , whereas the absorption rate of maximum of 1.7-fold compared with the control, and reverted to the control level within 2 days after the final felodipine ER is related to erosion of the hydrophilic matrix of the ER tablet, and drug absorption may be GFJ ingestion (Figure 3b) . Furthermore, the change of AUC ratio of felodipine in the presence of GFJ predicted lower in the more distal parts of the gastrointestinal tract [44] . It was suggested by the analysis using our model by this model corresponded well to the change in the ratio of active CYP3A4 content (e) to total CYP3A4. that twice the amount of GFJ would produce a maximum effect on felodipine pharmacokinetics (Figure 3 ). These
The change occurred within 4 h after GFJ ingestion. This result is consistent with the finding that reduction results were supported by the previous experimental data by Edgar et al. [1] , suggesting the validity of our model. of intestinal CYP3A4 content by GFJ occurred within 4 h at the Western blotting level [25] . The AUC of The estimated parameter values were 0.922 (AU −1 h −1 ) for K and 0.0849 (h −1 ) for k. The half-life time (t 1/2 ) is felodipine increased 1.5-fold compared with the control in the case of two ingestions of GFJ per day, and obtained as 8. 16 h, in reasonable agreement with t 1/2 of rat CYP3A1 protein (12±3 h) and heme (7±2 h) [43] .
1.65-fold in the case of 10 ingestions per day ( Figure 4b ). Next, we simulated the AUC of felodipine after three The repeated administration of GFJ during the day might be expected to produce a cumulative reduction of ingestions in 1 day with meals at 07.00 h, 12.00 h and 18.00 h. The e-value was reduced to 0.2 immediately CYP3A4 content and activity whereas this would not be the case for GFJ given only once daily. In developing after GFJ ingestion at 07.00 h and to 0.1 after GFJ ingestion at 12.00 h, then remained at 0.1 after our model, we analysed the elimination rate constant of active CYP3A4 independently of that of inactive GFJ ingestion at 18.00 h. After the three ingestions, it took 2.5 days for e to recover to the control level before CYP3A4, but found that this gave no improvement over the use of a single rate constant. Therefore, in this GFJ ingestion (Figure 5a) . Correspondingly, the AUC of felodipine increased 1.5-fold after GFJ ingestion at analysis, we assumed that their elimination rate constants are the same. It is desirable to minimize the number of 07.00 h, almost 1.6-fold after GFJ ingestion at 12.00 h, and to 1.6-fold after GFJ ingestion at 18.00 h. After the parameters to be estimated in this study because we have only 7 points as observed data. three ingestions, it took 2.5 days for the AUC value to revert to the original level before GFJ ingestion We next simulated the inhibition profiles of e after ingestion of GFJ at various amounts and frequencies by (Figure 5b) . We next conducted a simulation study of e and AUC using the estimated parameters. The AUC of felodipine 07.00 h, 12.00 h, 18.00 h) per day for 7 days. The e-value Science and Culture, Japan. varied between 0.2 and 0.7 after a single GFJ ingestion per day for 7 days, and it took 3 days for the e-value to References recover to the control value after the last GFJ ingestion (Figure 6a) . The AUC ratio varied between 1.1 and 1.5
